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Trust exerts a multidimensional influence at the interpersonal level in the clinical trials
setting. Trust and distrust are dynamic states that are impacted, either positively or
negatively, with each participant-clinical trials team interaction. Currently, accepted
models of trust posit that trust and distrust coexist and their effects on engagement
and retention in clinical trials are mediated by ambivalence. While understanding of trust
has been informed by a robust body of work, the role of distrust and ambivalence in the
trust building process are less well understood. Furthermore, the role of ambivalence
and its relationship to trust and distrust in the clinical trials and oncology settings
are not known. Ambivalence is a normal and uncomfortable state in the complex
decision making process that characterizes the recruitment and active treatment phases
of the clinical trials experience. The current review was conducted to understand
the constructs of ambivalence as a mediator of trust and distrust among vulnerable,
minority participants through different stages of the oncology clinical trials continuum,
its triggers and the contextual factors that might influence it in the setting of minority
participation in oncology clinical trials. In addition, the researchers have sought to link
theory to clinical intervention by investigating the feasibility and role of Motivational
Interviewing in different stages of the clinical trials continuum. Findings suggest that
ambivalence can be processed and managed to enable a participant to generate a
response to their ambivalence. Thus, recognizing and managing triggers of ambivalence,
which include, contradictory goals, role conflicts, membership dualities, and supporting
participants through the process of reducing ambivalence is critical to successfully
managing trust. Contextual factors related to the totality of one’s previous health-care
experience, specifically among the marginalized or vulnerable, can contribute to
interpersonal ambivalence. In addition, changes in information gathering as a moderator
of interpersonal ambivalence may have enormous implications for gathering, assessing,
and accepting health information. Finally, motivational Interviewing has widespread
applications in healthcare settings, which includes enabling participants to navigate
ambivalence in shared-decision making with their clinician, as well as executing changes
in participant behavior. Ultimately, the Integrated Model of Trust can incorporate the role
of therapeutic techniques like Motivational Interviewing in different stages of the clinical
trials continuum. Ambivalence is a key component of clinical trial participation; like trust,
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ambivalence can be managed and plays a major role in the management of trust in
interpersonal relationships over time. The management of ambivalence may play a major
role in increasing clinical trial participation particularly among the marginalized or the
vulnerable, who may be more susceptible to feelings of ambivalence.
Keywords: ambivalence, clinical trials, disparities, motivational interviewing, trust

TRUST, DISTRUST AND AMBIVALENCE

this review will consider how ambivalence can be mitigated
through evidence-based interventions, such as Motivational
Interviewing, and its potential applications in clinical trial
settings. Specifically, Motivational Interviewing has widespread
applications in healthcare settings, including assisting patients
to ameliorate ambivalence around shared-decision making with
their clinician, as well as changes in participant behavior (17).
Ultimately, the Integrated Model of Trust can incorporate the
role of therapeutic techniques like Motivational Interviewing in
different stages of the clinical trials continuum.

The decision to trust or distrust, in the context of clinical
trials and oncology care, is the product of the interactions
between trust, distrust, and ambivalence. Hillen et al. and
Hudson et al. (1, 2) Many factors influence this decision such
as prior participant trust experiences both within and outside
of the health-care system, provider factors that influence trust
such as communication, honesty, competence, and confidence,
health system, and institutional factors. Most important is
the relationship between the participant and clinical trials
team members that is constantly evolving as a result of
ongoing treatment, system related factors, and interparticipantal
engagement (3–9).
The relationship between trust, distrust, and ambivalence
has been evolving in recent years. Lewicki et al. (10) first
proposed that trust and distrust coexist and are moderated
by ambivalence. The model was expanded to include affect
based trust as well as attributes, characteristics and contextual
factors associated with distrust (11–13). Reich et al. (14) have
proposed that ambivalence is embedded in the definition of
trust in which one accepts vulnerability (negative attribute)
in exchange for “positive expectations of the intentions or
behavior of another in the future” (positive attribute). Trust
results as the consequence of accepting ambivalence rather than
vulnerability. Therefore, its relationship with trust and distrust
may be more intimate than previously accepted. More recently,
the Integrated Model of Trust has incorporated and adapted
the Lewicki model to the clinical trials setting (15). Trust and
distrust are dynamic states that are impacted, either positively
or negatively, with each participant-provider interaction in
the clinical trials setting. The psychological contract serves as
the vehicle through which trust and distrust are renegotiated.
Extrapolating this to the clinical trials setting, Hurd et al.
suggest that ambivalence, like trust, must also be managed. It is
subject to the same tensions that exist between participants and
clinical trials team members during the recruitment, retention,
surveillance phases of the clinical trials experience as well
as the care transition points that occur during transition
from the referral to treatment and treatment to surveillance
phases (15, 16).
Although knowledge of minority participant trust and distrust
in clinical trials and oncology care is expanding, there are
significant gaps in our knowledge of the role of ambivalence
in these settings. This review will explore the construct
of ambivalence, examine the triggers of ambivalence at the
individual level and consider the impact of contemporary and
societal factors on ambivalence that can affect participation
rates in clinical trial studies will also be explored. Finally,
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AMBIVALENCE
The presence of simultaneous, strong positive or negative
attitudes toward a participant, object or situation (entity) defines
ambivalence (10). These attitudes are based on differing qualities
or characteristics that are inherent in, or ascribed to, something
or someone (18). Ambivalence arises when an individual’s
expectations of a participant, object, or situation are opposed
to what is encountered or displayed. It creates a psychological
tension or conflict (subjective ambivalence) that occurs when the
participant is evaluating their attitudes toward an entity as well as
tension arising from the response to the attitude associated with
an entity (structural ambivalence) (19).
Ambivalence is often considered synonymous with
uncertainty, ambiguity or neutral attitudes. However, it is
distinct from these due to the presence of strong attitudes.
Specifically, uncertainty is associated with positive or negative
attitudes generated with diminished confidence. Ambiguity
arises from a lack of familiar cues, cues that have both positive
and negative characteristics or an abundance of cues that must
be evaluated and categorized. Neutral attitudes are characterized
by the absence of both positive and negative attitudes (20).
Individuals receive both positive and negative information
during interactions with others which must be evaluated and
ultimately assigned a positive or negative attribute. Positive
information results in assigning positive attributes to the
participant, object, or situation while negative information
results in assigning negative attributes. The quality and volume
of positive or negative attributes determines the strength of the
positive or negative attitude toward the participant, object or
situation (21, 22). Ambivalence arises when a person’s evaluations
of an object, person or situation, and the resulting attributes
that are repeatedly experienced over time, are inconsistent.
The Threshold Model of Ambivalence posits that ambivalence
does not exist in either a present or absent state (23).
Rather, it manifests over time once a critical threshold of
conflicting reactions is reached resulting in a participant feeling
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strong positive and negative attitudes, i.e., familiarity breeds
ambivalence. The threshold varies with the context and relevance
of the object, person or situation to the person experiencing
ambivalence. In this model the rate at which ambivalence
increases is slowed as the amount of conflicting information
increases once the threshold is crossed (23).
Ambivalence exerts both positive and negative effects which
can result in both good and bad outcomes (24). Historically
it was thought to be a negative state associated with high
uncertainty, negative thinking, bias, narrow thinking, reduced
ability to decide, resistance to change, decreased confidence
in attitudes, diminished processing of relevant information,
decisional paralysis and behavioral inflexibility (14, 25). However,
recent work has shown that ambivalence can have positive
effects. It increases information processing and can increase
cognitive breadth by forcing people to consider multiple
perspectives and unlearn inaccurate information/perceptions.
Furthermore, it increases behavioral flexibility and adaptability
to enable change in a participant’s viewpoint or actions
resulting in increased resilience to a stressor event and
lower ambivalence (26–28). Perhaps, most importantly, the
positive effects of ambivalence cause people to leverage their
collective wisdom by embracing the known and unknown,
acknowledging that the outcome of a situation is unpredictable
and linking prior knowledge and experiences to resolution of
ambivalence (29).
Ambivalence creates a psychologically stressful state of
varying intensity and the intensity of opposing attitudes
is directly linked to the ascribed importance of the issues
underlying ambivalence to the participant (30). Individual
susceptibility to ambivalence varies and the response to it may
be conscious or unconscious. Certain individual characteristics
like knowledge based investigative thinking, fear of invalidity,
low need for knowledge, age, and thoughtful approach to selfemotion are associated with ambivalence (14).
The overarching goal of a participant’s response to
ambivalence is to decrease the psychological discomfort to
a manageable level by resolving the incongruities between the
positive and negative information. People use three strategies
to decrease ambivalence- heuristic and systematic processing,
selectivity and compensatory perceptions of order. Heuristic
processing applies simple rules to judge information which
enables them to process conflicting and non-conflicting
information with the least expenditure of cognitive effort (Least
Effort Principle) and high confidence in their final judgement
(Sufficiency Principle) (31). A participant’s confidence in their
final judgment is constantly self monitored and depends upon
the participant and their motivational state. Heuristic processing
is not sufficient if a high level of confidence in a final judgement
is needed. If ambivalence cannot be reduced to a subthreshold
level systemic processing is employed. This approach requires
comprehensive analysis and scrutiny of any information that
will reduce or resolve ambivalence and is both cognitively
and temporally consuming. The outcomes of each of these
approaches are distinct. In summary, the heuristic approach is
efficient but does not produce durable perceptions and attitudes
that are stable over time. Conversely, systemic processing
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produces strong stable attitudes and perceptions and is a better
predictor of future behaviors (25).
Selectivity, occurs when a person only selects and retains
the information that supports their underlying positive or
negative attitude. Prior positive or negative experiences do not
influence the selectivity process, because it is employed when
a participant lacks knowledge about an issue (32). Selectivity
might be operative during the recruitment phase of the clinical
trials continuum. Thus, a participant with knowledge of prior
research abuses and who experiences both positive and negative
interactions during trial recruitment might selectively focus on
negative rather than positive attributes of the experience.
A third approach used to cope with ambivalence is
compensatory perceptions of order. Compensatory perceptions
allow people to avoid changing their underlying positive or
negative attitudes about an entity (33). Ambivalence is a
disordered and incongruous state and order is necessary to
effectively address it. To accomplish this, a person ascribes
false characteristics and/or qualities to the positive or negative
information based upon incorrect perceptions, or ascribes to
conspiracy theories that support negative perception. Finally,
it can also occur after having an experience that confirms an
underlying positive or negative belief.
Processing and managing ambivalence enables a participant
to generate a response to their ambivalence. Ashforth et al. (34)
have proposed four distinct responses to ambivalence that people
employ based upon the situation in which ambivalence arises:
avoidance, compromise, domination and holism (Table 1). Each
response occurs along a continuum of positive and negative
attitudes and, in turn, can have either positive or negative
outcomes.
Avoidance is used when a participant believes that the
source of ambivalence must be endured instead of managed,
is situationally influenced and does not involve overt behaviors
(35, 36). It allows participants to rely on defense and
coping mechanisms to reduce the psychological tensions
directly associated with the source of ambivalence. The
defense mechanisms (denial and splitting) are unconscious and
protective in nature while coping mechanisms are solution
focused, conscious and intentional. Denial allows participants to
reject, reinterpret, forget or diminish disagreeable information.
Splitting enables them to separate the positive and negative
orientations, suppress one or the other and reduce ambivalence.
Avoidance does not address the root cause(s) of ambivalence
and can obscure them from the participant. However, it can be
useful when the participant cannot address the underlying issue
effectively (power imbalance) or when the positive and negative
feelings are not in conflict as might occur in subthreshold phases
of the threshold model (23).
Domination, also a defense/coping mechanism, occurs in
the hybrid settings of high negative and low positive and
low negative and high positive evaluation. It is a reactive
mechanism which unlike avoidance is associated with taking
action. When utilized the participant exaggerates either the
positive or negative evaluation so that it dominates the other
orientation and decreases ambivalence. The dominated element
continues to exist and may become dominant over time as
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several negative aspects of holism. It can decrease confidence
and hinder action. It can increase ambivalence since both the
positive and negative attitudes are kept. Finally, the final result of
the holism response occurs over time during which the negative
aspects of ambivalence can be more pronounced.
There are five factors that moderate ambivalence: free choice,
information events, attitudes toward people compared to idea,
safe relationships and role and task demands (14). Free choice
determines whether ambivalence will result in commitment to
trust or not to trust by increasing consistency and stability. Its
influence lies in not forcing a participant to choose but, instead,
allowing them to keep their ambivalence and reduce the negative
effects of ambivalence over time. Information about a participant,
relationship or situation that underlies ambivalence affects
whether a participant will form positive or negative attitudes.
Positive information results in a positive attitude while negative
information produces a negative attitude. However, while the
information itself is important, the quantity and intensity of the
information whether positive or negative will directly influence
whether one forms positive or negative attitudes. While attitudes
toward people and ideas can both moderate ambivalence,
those associated with people have more influence and will
stimulate stronger desires to decrease ambivalence via less flexible
responses. Safe family relationships or supportive social networks
moderate ambivalence by providing strong support that can
transform ambivalence about trusting to a commitment to trust.
Finally, task and role demands moderate ambivalence in several
ways. Integrative rather than distributive tasks favor the positive
effects of ambivalence, are proactive in nature and create win-win
situations for both parties. Role demands depend upon who has
the power within a relationship and whether that participant is
ambivalent. Ambivalent people with power cause those without
power to disengage. Furthermore, the judgments that ambivalent
empowered people make have little influence and are perceived
to be of lower quality by the participant with lesser power.
Recognizing and managing ambivalence is important and central
to this process are the triggers that lead to ambivalence.

TABLE 1 | Responses to ambivalence (34).
Positive orientation toward
clinical trials participation
Negative
orientation
toward clinical
trials
participation

Low

Low

Avoidance

Intermediate
High

Intermediate

High

Domination
Compromise

Domination

Holism

Adaptive responses to ambivalence among minority participants in clinical trials.

situations change. Domination is useful when a participant must
choose between two mutually exclusive actions, one orientation
is counterproductive or the core elements of a positive or
negative evaluation don’t need to be maintained. However,
domination can create highly dysfunctional states when both
positive and negative orientations must be maintained or the
initial orientation is salient or the decision is based solely on
relieving the psychological discomfort (34).
Compromise occurs when positive and negative evaluations
are both accommodated through reciprocal concessions. It is
action oriented and can be accomplished by evaluating the
positive and negative attributes and finding a middle ground that
is neither positive nor negative or keeping compatible elements
of both the positive and negative attributes. Compromise is most
effective when neither the positive nor negative attributes are
sufficient to favor one attitude over another but the core attitudes
can be maintained and when the participant is able to act upon
the evaluation. Loss of the core positive or negative attitudes
results in a dysfunctional compromise.
Holism, a coping mechanism, is action oriented and results
when both the positive and negative attitudes can be accepted.
It is likely the best approach to decreasing and resolving
ambivalence. In the setting of ambivalence where the positive
and negative attitudes are strong, wisdom, the result of prior
experience, and learning moderates attitudinal differences.
Wisdom is gained through mindfulness, both/and thinking
and informed choice. Mindfulness occurs when a participant
is open to new information, aware of multiple perspectives
and can create new categories of meaning of positive and
negative attitudes (37). Both/and thinking enables a participant
to discover unconscious and conscious attitudes by actively
comparing the positive and negative attitudes and discovering
shared and distinct characteristics of them thereby undoing
the suppression that occurs with the dominant response to
ambivalence. Informed choice enables a participant to commit
to an attitude (trust vs. mistrust), and the commitment results
from knowledge of both the positive and negative attitudes that
enable one to decide to trust or not. The positive effects of holism
allow a participant to resolve ambivalence in a way that embraces
both positive and negative attitudes, increases understanding of
the attitude that results in a commitment, enables situational
adaptability and positively influences the individual. There are
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TRIGGERS OF AMBIVALENCE
Understanding the triggers of ambivalence can yield an expedited
path to ambivalence resolution. Sociologists and psychologists
have varying views on the sources of ambivalence. Sociologists
ascribe its origination to norms and roles, whereas psychologists
attribute ambivalence to individual differences and relationships
(34). Triggers of ambivalence can pertain to both individuals and
organizations with each of them experiencing and operating in
environments that are complex and dynamic. Since this research
focuses on individuals and the ambivalence they experience, the
triggers of ambivalence will be discussed from the individual
perspective. Ashforth et al. (34) delineate four main types
of triggers of ambivalence “(1)...contradictory goals and role
conflicts; (2) membership dualities; (3) multifaceted objects; and
(4) temporal factors” (34).
Competing expectations, beliefs, and behaviors can foster
contradicting goals and conflicts in roles. Women in “high-status
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distrust—as mediated by the construct of ambivalence—within
a myriad of cultural, social, and interparticipantal relationships
(10).
Prior research regarding the barriers to clinical trial
participation indicates that individual health care experiences
vary by race, ethnicity, gender, age, and geographic location,
i.e., rural vs. urban residents (41). In current research, potential
patients manage ambivalence by operationalizing barriers as
trusting and distrusting relationships, i.e., as trust or distrust of
the health-care system and/or ambivalence about the system, and
even in terms of their relationship with the physician (42, 43).
There are many barriers to participation in clinical trials.
Barriers such as the totality of previous health-care experiences,
including lack of access to care, lack of transportation to
receive care, prior experiences of health care discrimination, selfreported health status, income status, and level of education, (41,
44) can contribute to interpersonal ambivalence (20). Variables
included in the following discussion that may have particular
relevance in the management of ambivalence and clinical trial
participation, also include the structure of the health-care system,
and how health-related information is gathered, processed, and
shared.
Interpersonal relationships “guided by past experiences and
relationships that that may have been seen as trusting/distrusting
and trustworthy/untrustworthy behavior” (10) may vary based
on one’s ethnicity, age or gender. It may only be possible
to hypothesize about the impact of one’s past experiences
on one’s level of trust (45, 46). Yet, past atrocities, such as
slavery, infamous research trials, e.g., The U.S. Public Health
Service Syphilis Study at Tuskegee, and the Guatemalan study
continue to haunt the psyche of many Americans. For older
individuals„ these atrocities seem to continue to inform current
health choices (47). In Shavers et al. (47), 81 percent of
African Americans, and 28 percent of white respondents “were
aware” of the Tuskegee study. Forty-nine percent of the African
Americans and 17 percent of whites indicated that this knowledge
would negatively impact their decision to participate in a
clinical trial (47). In studies of patient’s reasons for nonparticipation in cancer clinical trials, lack of knowledge about
cancer terminology, distrust of the medical system, and trust in
physicians remained constant themes in focus group discussions
about reasons for and against trial participation (42, 44). To
manage ambivalence, Reich and Wheeler (14) found that in
some instances people “cultivate ambivalence as an emotional
hedge” in case what they desire may be out-of-reach. In short,
if one has had negative experiences in the past or may have
low expectations about their ability to be included or access
a trial, ambivalence may be a useful emotion. Understanding
the impact of the past, while developing new experiences
that allow new stories of trust may be yet another method
to begin to address ambivalence among prospective research
participants.
Interpersonal relationships also may be mediated by the social
context, which may be defined as the structure of the healthcare system–to the extent that the system remains difficult
to maneuver, difficult to access and quality of care may be
dependent upon the patient’s ability to pay or income status.

positions” can experience emotional ambivalence because from
one aspect there is positive affect from attaining professional
goals, and from another aspect negative affect can result from
pressure to behave and conform to stereotypical gender roles
(34). Contradictory goals manifest when the pursuit of one goal
conflicts or undermines the pursuit of another goal, in other
words, goal conflict (38).
Membership dualities provoke ambivalence because of the
simultaneous requirement to do Activity A and to do the
opposing action of Activity A (34). Dualities can be seen
as oxymorons, paradoxes, ironies, and even dilemmas, hence
triggering ambivalence (34, 39). A classic example of membership
duality is the “paradox of belonging,” retaining individuality
while adhering to group commonality. Another common duality
is the “paradox of engaging,” trusting group members before trust
is proven (34, 39).
Multifaceted objects evoke ambivalence because opposing
attributes can surface over time. This attribute is often manifested
in individuals’ lives in the workplace and in relationships. The
more knowledge attained and varied the experiences, the greater
the storage of information and the greater the familiarity with the
object, leading to encounters with the multiple imperfect facets.
In other words, “Familiarity breeds ambivalence” (40).
Lastly, temporal factors give opportunities for “oppositional
tendencies” which trigger ambivalence (34). Reflecting on past
events conjures “counterfactual thinking” (34). A positive event
can be reflected upon with an opposing statement such as
“it could have been better” while a negative event can be
characterized as, “it could have been worse” (34).
The explanation of these triggers elucidates the different
social and psychological pathways to trigger ambivalence
in individuals. Ambivalence causes the individual to be
uncomfortable and stressed because of cognitive processing of
the complex and dynamic attributes of the positive and negative
elements and aspects of the object (27).

BARRIERS TO HEALTH CARE: EXTERNAL
TRIGGERS OF AMBIVALENCE
There are challenges to understanding ambivalence as it relates
to health care, in general, and to clinical trial participation, in
particular. First, in a patient-centered, health-care environment,
it is necessary to understand the role that external factors
may play as possible promoters and inhibitors in building and
sustaining trusting relationships. And second, while there is a
large body of research on trust, and a small body of research
on distrust, our understanding of the role of ambivalence in
the individual’s clinical trial, decision-making process has yet
to be explored. Critical to our understanding of how people
manage ambivalence will be to understand how people use their
experiences and interactions within the health-care system to
navigate the process of resolving ambivalence.
The health care experience does not take place within a social
vacuum. To fully understand, to measure, to improve and to
enhance conditions of trust in clinical trial participation it is
necessary to address the far-reaching implications of trust and
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(45, 48) It is imperative be mindful of the “the uniqueness
of the health-care relationship,” (48) with the patient and the
provider not sharing equal power in the relationship. Eliminating
these disparities is politically sensitive and challenging (49). The
health-care system—as a whole—may be viewed in society as a
continuation of structures and policies that produce inequalities
in general (49). One primary example is the inconsistency of
current health-care legislation. In one instance, health policy
sought to increase the inclusion of women and the underserved
in accord with the 1993 Legislation, which called for an increase
in clinical trial participation. Legislation such as the Affordable
Care Act, which includes a provision to allow private insurers
to cover the cost of some routine patient care for participation
in cancer clinical trials, has resulted in claim denials, which may
prove to be yet another barrier to clinical trial participation (50).
Ambivalence may be triggered by uncertainty. Uncertainty is a
response to lack of information and knowledge, which may make
it difficult to know how to feel about an issue (14).
Changes in information gathering as a moderator of
interpersonal ambivalence—in an age of burgeoning social media
usage and reliance—has enormous implications for gathering,
assessing, and accepting health information. To date, few
studies have explored the impact of social media usage for
information seeking as enhancing or diminishing interpersonal
ambivalence (32). How information about a vast number of
experiences—to which we may not be privy, but to which
we now may feel connected—is shared and processed may
take on greater meaning in the future “when constructing
informational environments” (32). Ambivalent opinions may
be tempered by several variables, including attitude strength,
which information to seek or ignore, cognitive dissonance, and
the amount of participant knowledge about an issue (32). How
the use of social media, e.g., Facebook, Instagram, WhatsApp,
Twitter, has negatively or positively engendered public trust gives
rise to numerous questions (32). Mixed messages about health
confound the public trust (51). What impact did social media
have—in retrospect—in shaping the saliency and informationseeking activities among various groups about issues such as
vaccine, or research trial safety? McConnel (52) in his review of
the role of mental health treatment and social support, concludes
that “individuals draw social support from their relationships.”
Is electronic connectivity a fulfilling relationship in terms of
what we now define as social support? People exercise the
ability to seek information based on individual attitudes and
motivation (32). Among the various cultures, what impact will
social media have on information seeking behavior? African
Americans’ beliefs about white society’s devaluation of black lives
and ongoing conspiracy against the race has had a long-lasting
impact on relationships with the health profession (53). In the
era of “fake news,” how does one determine what is real and what
is not?
Access to different electronic channels, provides the
opportunity to strengthen communication and the capacity
of providers to serve the underserved (49). Ambivalence
among individuals/patients does not remain static. The
individual/patient can change rapidly both positively and
negatively and reverse again slowly or just as rapidly. This rate
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and speed of change is where social media can act as a retardant
or accelerant in shaping positive or negative opinions. In light
of the above considerations, managing and mediating patient
ambivalence in health care settings is an important component
of clinical trial participation.

MOTIVATIONAL INTERVIEWING
In this review, trust, distrust, and ambivalence have been
clearly delineated in relation to clinical trials participation.
Furthermore, individual triggers and societal factors affecting
ambivalence have also been examined. The relationship between
these factors ultimately impacts voluntary participation in
clinical trials. Voluntary patient participation, based on the
premise of a patient’s trust, is a crucial aspect of clinical
trial participation and healthcare treatment. Ambivalence is a
normal and uncomfortable component of the complex decisionmaking process when one is considering a change (54, 55).
It is necessary, then, to create opportunities for change by
reducing ambivalence. Increasing trust includes assisting patients
to ameliorate ambivalence around shared-decision making with
their clinician, as well as make changes in participant behavior
(17). Changing behaviors and making decisions arises from
addressing and managing a patient’s level of ambivalence.
This includes (1) engaging; creating a relationship between the
clinician and patient; (2) focusing; exploring the direction of
change; (3) evoking; eliciting the patient to state their own
reasons for changing; and (4) planning; creating an action plan
(17). By addressing a patient’s own reasons for ambivalence
toward making a decision or preparedness to make a change, a
provider can use “change talk” to reduce that patient’s resistance
to participating in treatment (56). Motivational Interviewing
(MI) focuses on using therapeutic techniques to address
such ambivalence in relation to change and has widespread
applications in healthcare settings.
MI allows the clinician to engage with a patient
collaboratively, rather than using a prescriptive or actionoriented approach. Research reports the use of five specific
skill-based strategies used within the MI framework to address
ambivalence. These include open-ended questions, affirmations,
reflections, and summaries, also known as “OARS” (56). MI
employs active listening skills, including reflecting what the
participant has said and asking questions without specific “yes”
or “no” answers (57). Rather than asking a patient to address
an issue with a specific answer, such as a closed question, MI
allows the patient to answer a question on his or her own
terms and to self-identify the reasoning behind his or her
willingness to change a certain action or behavior in relation to
his or her healthcare treatment (56). By demonstrating to the
patient that the clinician has compassion, empathy, and a clear
understanding of that patient’s multi-faceted problem, which
may involve many levels of inconsistencies that promote feelings
of ambivalence (23), motivational interviewing allows the patient
to fundamentally address his or her readiness for change (58).
MI can address a wide variety of behaviors related to treating
chronic health diseases (16). More specifically, there is evidence
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that may suggest MI can assist patients with cancer to address
psychosocial needs, as well as contemplate changes in lifestyle
behaviors, such as diet, exercise, and smoking cessation (58).
In a meta-study that evaluated 48 studies utilizing MI as an
intervention tool, the use of MI increases the chance of a positive
outcome by 55%. Positive outcomes include changes in physical
prognostic markers, decreased alcohol and substance use, and
increases in following medical advice, such as monitoring
blood sugar levels, increasing physical activity, and increased
confidence on managing chronic health conditions. However,
there were other outcomes that had mixed results or that had
negative results based on MI, including behaviors that focus
on risk-reduction, other physical functioning outcomes, and
markers of quality of life, such as depression, anxiety, pain, and
adjustment to diseases (59).
Research has even shown that MI techniques have been used
by practice oncology nurses for pain management in patients
with cancer (60). In addition, MI may benefit cancer survivors,
including helping patients to lose weight, increase overall quality
of life, and improve clinical biomarkers (61). Furthermore,
when MI is provided for patients undergoing treatment for
cancer, there may be a higher likelihood that patients will feel
optimistic about the future and increase confidence around
participant healthcare management and decision-making (62).
MI may also assist with increasing health screenings outcomes
for patients who could potentially have cancer, among other
diseases and illnesses (63). Additionally, MI has applications in
clinical trials and has been utilized in a various studies, including
substance abuse, homelessness, and medication adherence. For
instance, MI has been effective in clinical trials at promoting
smoking cessation (64). Motivational interviewing has even been
shown to promote changes in behavior that lead to increased
medication adherence (65). Clearly, there is a significant amount
of empirically-supported evidence suggesting that clinicians
who utilize MI in practice are actively decreasing ambivalence,
establishing strong rapport and trust with their patients, as
well as increasing patients’ overall quality of life. Ultimately,
this enables these patients to make healthcare decisions that
are based on self-efficacy and self-determination. However, in
the healthcare industry, there may be little awareness about
how to utilize motivational interviewing among front-line
professionals (66).

There is also little information in the literature about the
relationship between MI and trust. While there is supporting
literature that conceptualizes the relationship between trust and
ambivalence, as has been discussed in this article, there is little
evidence that directly evaluates the impact of MI on levels
of trust. Given the evidence on the role of MI in managing
ambivalence in a multitude of studies and clinical trials, it is
plausible to consider that MI also has an impact that would lead
to increased trust and, presumably, decreased distrust. Future
studies should consider the role of motivational interviewing
and its relationship to trust, distrust, and ambivalence. Such
studies should also evaluate the use of MI in clinical oncology
trials, as well as other cancer-related treatment and prevention
programs. Such studies should emphasize the role of MI in
reducing ambivalence as well as increasing trust, engagement,
and rapport between the client and patient. There are also a
myriad of other outcomes that could be considered for such
studies, including increases or improvements in participation
rates for vulnerable and marginalized populations, perceived
quality of treatment, as well as participants’ willingness to change
lifestyle factors impacting healthcare management.
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